These transgenic mice express a tamoxifen-inducible Cre recombinase driven by the mouse Col1a2, collagen, type I, alpha 2, promoter. The transgene insert contains a fusion product involving Cre recombinase and a mutant form of the mouse estrogen receptor ligand binding domain. The mutant mouse estrogen receptor does not bind natural ligand at physiological concentrations but will bind the synthetic ligand, 4-hydroxytamoxifen. Restricted to the cytoplasm, the Cre/Esr1 protein can only gain access to the nuclear compartment after exposure to tamoxifen. When crossed with a strain containing a loxP site flanked sequence, the offspring are useful for generating tamoxifen-induced, Cre-mediated targeted deletions of the flanked sequence. Tamoxifen administration in double mutant mice, carrying this transgene and a beta-galactosidase reporter, induces Cre recombination in dermal and visceral fibroblasts. The Donating Investigator reports that homozygous mice do not breed well. Hemizygous mice are viable and fertile.
 Of note, The Jackson Laboratory live colony of Stock No. 029235 shows transgene carrier and noncarrier mice exhibit white belly spots [November 2019].
 Col1a2-CreER transgenic mice will also be available on a C57BL/6J congenic background (Stock No. <a href="https://www.jax.org/strain/029567">029567</a>).

 This Col1a2 Cre-ER mutant mouse strain carries a transgene with tamoxifen inducible Cre recombinase and may be useful for generating fibroblast specific targeted mutants for studies of fibrotic diseases, wound healing and connective tissue physiology, as well as fibroblast lineage fate mapping.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.

STOCK Tg(Col1a2-cre/ERT -ALPP)7Cpd/J Frozen Embryo